These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37951571)

  • 41. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
    Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
    Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Unsupervised clustering analysis based on multidimensional features reveals distinct clinical characteristics and associated factors of different phenotypes in patients with chronic rhinosinusitis with nasal polyp].
    Huang JY; Luo YG; Lyu H; Liu D; Wang YF; Liu PQ; Tan L; Xiang R; Zhang W; Xu Y
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Jun; 59(6):590-601. PubMed ID: 38965849
    [No Abstract]   [Full Text] [Related]  

  • 43. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
    Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
    Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
    Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
    Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement in health-related quality of life questionnaires with biologic treatment in severe asthma and comorbid chronic rhinosinusitis with or without nasal polyposis: a real-life experience.
    Santus P; Saad M; Casartelli A; Lorusso R; Milani L; Danzo F; Busatto P; Radovanovic D
    Ann Med; 2024 Dec; 56(1):2407523. PubMed ID: 39373532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pleiomorphism of the cytokine profile in nasal polyp tissue depending on the phenotype of chronic rhinosinusitis with nasal polyps].
    Savlevich EL; Zurochka AV; Kurbacheva OM; Egorov VI; Shilovskiy IP; Mitrofanova ES; Lyubimova EV
    Vestn Otorinolaringol; 2023; 88(1):50-56. PubMed ID: 36867144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: A systematic review.
    Aldajani A; Alroqi A; Alromaih S; Aloulah MO; Alsaleh S
    Am J Otolaryngol; 2022; 43(6):103615. PubMed ID: 36057193
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving predictability of IgE-high type 2 chronic sinusitis with nasal polyps in the biologic era.
    Heffernan A; Phulka J; Thamboo A
    J Otolaryngol Head Neck Surg; 2022 May; 51(1):22. PubMed ID: 35606866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Central compartment atopic disease: prevalence of allergy and asthma compared with other subtypes of chronic rhinosinusitis with nasal polyps.
    Marcus S; Schertzer J; Roland LT; Wise SK; Levy JM; DelGaudio JM
    Int Forum Allergy Rhinol; 2020 Feb; 10(2):183-189. PubMed ID: 31600866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
    Santomasi C; Buonamico E; Dragonieri S; Iannuzzi L; Portacci A; Quaranta N; Carpagnano GE
    Acta Biomed; 2023 Feb; 94(1):e2023028. PubMed ID: 36786266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
    Al-Ahmad M; Ali A; Khalaf M; Alterki A; Rodriguez-Bouza T
    BMC Pulm Med; 2023 Jul; 23(1):266. PubMed ID: 37464395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
    Hoy SM
    Drugs; 2020 May; 80(7):711-717. PubMed ID: 32240527
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
    Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
    J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
    Tversky J; Lane AP; Azar A
    Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nasal interleukin 25 as a novel biomarker for patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness: A pilot study.
    Chen F; Hong H; Sun Y; Hu X; Zhang J; Xu G; Zhao W; Li H; Shi J
    Ann Allergy Asthma Immunol; 2017 Oct; 119(4):310-316.e2. PubMed ID: 28870448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting.
    Benjamin MR; Stevens WW; Li N; Bose S; Grammer LC; Kern RC; Tan BK; Conley DB; Smith SS; Welch KC; Schleimer RP; Peters AT
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):1010-1016. PubMed ID: 30368005
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Omalizumab in patients with NSAIDs-exacerbated respiratory disease.
    Forster-Ruhrmann U; Stergioudi D; Pierchalla G; Fluhr JW; Bergmann KC; Olze H
    Rhinology; 2020 Jun; 58(3):226-232. PubMed ID: 32077449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
    Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
    Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps.
    Haxel BR; Hummel T; Fruth K; Lorenz K; Gunder N; Nahrath P; Cuevas M
    Rhinology; 2022 Dec; 60(6):435-443. PubMed ID: 36150163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.